Detailed analysis of a randomized phase III trial: Can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?

Annals of Oncology

Volumn 17, Issue 9, 2006, Pages 1379-1385

  Leonard, Robert ^a   O'Shaughnessy, J ^b   Vukelja, S ^c   Gorbounova, V ^d   Chan Navarro, C A ^e   Maraninchi, D ^f   Barak Wigler, N ^g   McKendrick, J J ^h   Harker, W G ⁱ   Bexon, A S ^j   Twelves, C ^k  

^a SINGLETON HOSPITAL   (United Kingdom)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c Tyler Cancer Center   (United States)

^d INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^e HOSPITAL DE ESPECIALIDADES   (Mexico)

^f INSTITUT PAOLI CALMETTES   (France)

^g TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^h BOX HILL HOSPITAL   (Australia)

ⁱ Utah Cancer Specialists   (United States)

^j HOFFMANN LA ROCHE INC   (United States)

^k UNIVERSITY OF BRADFORD   (United Kingdom)

more..

Author keywords

Capecitabine; Docetaxel; Dose reduction; Metastatic breast cancer; Safety

Indexed keywords

CAPECITABINE; DOCETAXEL; DOXORUBICIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STOMATITIS; SURVIVAL RATE;

EID: 33748755039     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl134     Document Type: Article

References (20)

1. Nabholtz JM, Senn HJ, Bezwoda WR et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999; 17: 1413-1424.
2. Miwa M, Ura M, Nishida M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274-1281.
3. Schüller J, Cassidy J, Dumont E et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45: 291-297.
4. Blum JL, Jones SE, Buzdar AU et al. Mulicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17: 485-493.
5. Blum JL, Dieras V, Lo Russo PM et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001; 92: 1759-1768.
6. Blum J, Jones S, Buzdar A. Capecitabine (Xeloda®) in 162 patients with paclitaxel-pretreated MBC: Updated results and analysis of dose modification. Eur J Cancer 2001; 37 (Suppl 6): S190.
7. Reichardt P, von Minckwitz G, Thuss-Patience PC et al. Multicenter phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer, relapsing after treatment with a texane-containing chemotherapy. Ann Oncol 2003; 14: 1227-1233.
8. Fumoleau P, Largillier R, Clippe C et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 2004; 40: 536-542.
9. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792-799.
10. Pronk LC, Vasey P, Sparreboom A et al. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br J Cancer 2000; 83: 22-29.
11. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002; 20: 2812-2823.
12. Beslija S, Obralic N, Basic H et al. A single institution randomized trial of Taxotere (T) and Xeloda (X) given in combination vs. Taxotere (T) followed by Xeloda (X) after progression as first line chemotherapy (CT) for metastatic breast cancer (MBC). Eur J Cancer Suppl 2005; 3: 114 (Abstr 407).
13. Twelves CJ, Fumoleau P, Jones SE et al. Adding Xeloda (capecitabine) to docetaxel significantly improves survival and does not compromise quality of life in patients with metastatic breast cancer. Breast Cancer Res Treat 2001; 69: 307 (Abstr 542).
14. Cassidy J, Twelves C, Van Cutsem E et al. First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13: 566-575.
15. Van Cutsem E, Findlay M, Osterwalder B et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study. J Clin Oncol 2000; 18: 1337-1345.
16. Mouridsen H, Harvey V, Semiglazov V et al. Phase III study of docetaxel 100 versus 75 versus 60 mg/sqm as second line chemotherapy in advanced breast cancer. Breast Cancer Res Treat 2002; 76 (Suppl 1): S88 (Abstr 327).
17. Torrecillas L, Soto C, Cervantes G et al. Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): Sequential vs. combined therapy results from the Mexican Oncology Study Group. Breast Cancer Res Treat 2004; 88 (Suppl 1): S200 (Abstr 5048).
18. Gradishar WJ, Meza LA, Amin B et al. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: A multicenter phase II study. J Clin Oncol 2004; 22: 2321-2327.
19. Blum JL, Dees C, Negron A et al. A phase II trial of combination therapy with capecitabine (C) and weekly paclitaxel (P) for metastatic breast cancer (MBC): Preliminary results in taxane-naïve patients. Breast Cancer Res Treat 2004; 88 (Suppl 1): S202 (Abstr 5053).
20. Joensuu H, Hemminki A, Tanner M et al. Phase III, randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) +x(CEX) vs. T followed by C + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): An interim safety analysis. J Clin Oncol 2005; 23: 57s (Abstr 719).